

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasarji Road, Andheri East, Mumbai 400 093

UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPT 30, 2011

Rs. Million

Particulars	Quarter ended	Quarter ended	Nine Months ended	Nine Months ended	Year ended
	30.09.2011 Unaudited	30.09.2010 Unaudited	30.09.2011 Unaudited	30.09.2010 Unaudited	31.12.2010 (Audited)
1.(a) Net Sales	3,127	2,756	8,918	7,965	10,850
(b) Other Operating Income	223	180	649	539	746
Total	3,350	2,936	9,567	8,524	11,596
2 Expenditure					
(a) (Increase)/decrease in stock in trade and work in progress	185	(236)	(6)	(131)	(149)
(b) Consumption of raw materials	1,172	1,200	3,623	3,270	4,484
(c) Purchase of traded goods	252	359	859	813	1,055
(d) Employees cost	415	394	1,261	1,178	1,633
(e) Depreciation	61	53	169	143	197
(f) Other expenditure	600	614	1,815	1,631	2,396
(g) Total	2,685	2,384	7,721	6,904	9,616
3 Profit from Operations before Other Income and Interest (1-2)	665	552	1,846	1,620	1,980
4 Other Income	146	133	458	253	389
5 Profit before Interest (3+4)	811	685	2,304	1,873	2,369
6 Interest	-	-	-	-	29
7 Profit before tax and Exceptional items (5-6)	811	685	2,304	1,873	2,340
8 Tax expense	263	212	753	615	790
9 Net Profit for the period before Exceptional items (7-8)	548	473	1,551	1,258	1,550
10 Exceptional item (net of tax)	-	-	-	-	757
11 Net Profit for the period after Exceptional items (9+10)	548	473	1,551	1,258	2,307
12 Paid-up equity share capital (Face Value of Rs. 10 per share)	230	230	230	230	230
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year					9,748
14 Earnings Per Share (EPS) before Exceptional items (Rs.) (Basic and diluted EPS for the period and for the previous year) (Not Annualised)	23.83	20.57	67.43	54.70	67.39
15 Earnings Per Share (EPS) after Exceptional items (Rs.) (Basic and diluted EPS for the period and for the previous year) (Not Annualised)	23.83	20.57	67.43	54.70	100.30
16 Public Shareholding					
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%	39.60%
17 Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered					
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%	60.40%

R O 3

Notes:


1. The above results were approved by the Board of Directors of the Company at its Meeting held on November 14, 2011.
2. In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended September 30, 2011.
3. The Board of Directors had declared an Interim Dividend of Rs.4 per Equity share of Rs.10 for the year ending December 31, 2011. The Dividend (including Dividend Distribution Tax) amounted to Rs.107 million. The said dividend was paid on August 18, 2011 through National Electronic Clearing Service/Dividend Warrants.
4. The break up of Net Sales is as follows:

	Rs. Million					
	Quarter ended Sept 30, 2011	Quarter ended Sept 30, 2010	Growth %	Nine Months ended Sept 30, 2011	Nine Months ended Sept 30, 2010	Growth %
Domestic Sales	2,575	2,320	11.0%	7,236	6,469	11.9%
Export Sales	552	436	26.6%	1,682	1,516	10.9%
Total Sales	3,127	2,756	13.5%	8,918	7,985	11.7%

5. The Company has a single business segment namely 'Pharmaceutical Business'.
6. The Company entered into a definitive agreement, on August 24, 2011, with Universal Medicare Private Limited to acquire its business of marketing and distribution of branded nutraceutical formulations in India. The transaction was closed on November 3, 2011 on fulfillment of all the conditions precedent.
7. Information on investor complaints is furnished below:

Pending as on July 1, 2011	Received during the quarter	Disposed of during the quarter	Pending as on Sept 30, 2011
Nil	26	26	Nil
8. The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED



DR. SHAILESH AYYANGAR
MANAGING DIRECTOR

November 14, 2011

